JCCT- Juno NW Houston

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes8 trials
• Obesity5 trials
• Type 1 diabetes2 trials
• Osteoarthritis1 trial

Phase

• Phase 39 trials
• Phase 22 trials

Status

• Completed4 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials

Lead sponsor

• Novo Nordisk A/S9 trials
• Pfizer2 trials

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Phase 3· Pfizer· Source

• Recruiting

  Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

  NCT07817251· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

  NCT07797335· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Phase 2· Pfizer· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

  NCT07415954· Phase 2· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes3 recruiting
• Obesity2 recruiting
• Osteoarthritis1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Novo Nordisk A/S· Source